What do systematic reviews say?

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with usual pharmacological care alone (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 0.92 [0.53, 1.6]
  6 studies · 235 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 119 participants
  Low